Mar 26th 2013 - Edison Investment Research today published a report on TopoTarget entitled "Progressing Well Towards Filing". In summary, the report says: Topotarget's key asset belinostat remains on track to be filed with the FDA for the treatment of peripheral T-cell lymphoma in mid-2013 and be approved in H114.
http://www.stockopedia.co.uk/research/progressing-well-towards-filing-71953/
http://www.stockopedia.co.uk/research/progressing-well-towards-filing-71953/
No comments:
Post a Comment